AbbVie ABBV stock has risen 30.7% in the past six months compared with an increase of 8.9% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart ...

AbbVie (NYSE:ABBV) on Thursday recorded better-than-expected financials for Q2 2025 and raised its full-year earnings outlook as the company’s newer immunology drugs offset a sharp sales decline for ...

The company's ability to hold off generic competitors long enough to develop a pair of replacement drugs for Humira that are ...

Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration Feb 4 (Reuters) - AbbVie forecast 2026 profit above Wall Street ...

AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing its ...

Oct 25 (Reuters) - AbbVie Inc on Friday reported stronger-than-expected results for the third quarter, as booming sales of its Humira arthritis treatment and Synthroid thyroid replacement drug more ...